Sichuan Biokin Launches Phase III Trial for BL-B01D1 in Urothelial Carcinoma
China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced the first patient enrollment in...
Drug
AbbVie’s Rinvoq Approved in EU for Giant Cell Arteritis
US-based pharmaceutical giant AbbVie (NYSE: ABBV) announced that it has received marketing approval in the...
Bristol-Myers Squibb’s Opdivo/Yervoy Combo Approved for MSI-H Colorectal Cancer
Bristol-Myers Squibb (BMS, NYSE: BMY) announced this week that the US Food and Drug Administration...
Yifan Pharma Secures NMPA Approval for Generic Sedapain
China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) has announced that it has received marketing approval...
Yunnan Baiyao’s INR102 Gains NMPA Clinical Trial Clearance for Prostate Cancer
Yunnan Baiyao Group Co., Ltd (SHE: 000538), a traditional Chinese medicine (TCM) company based in...
Bayer Submits Eylea 8 mg for RVO Macular Edema Approval in EU
German pharmaceutical giant Bayer (ETR: BAYN) announced that it has submitted an indication approval filing...
Daiichi Sankyo and AstraZeneca’s Datroway Approved in EU for Breast Cancer
Japan-based Daiichi Sankyo (TYO: 4568) and UK major AstraZeneca (NASDAQ: AZN) announced that their co-developed...
Winsunny Pharma’s FY101 Gains NMPA Clinical Approval for Hyperlipidemia
China-based Beijing Winsunny Pharmaceutical Co., Ltd (SHA: 601089) announced that it has received clinical approval...
Zhifei Biological Gains Bangladesh Approval for Dysentery Vaccine Trial
China-based Chongqing Zhifei Biological Co., Ltd (SHE: 300122) has received clearance from the Directorate General...
Hengrui Pharmaceuticals’ Vunakizumab Approved for Ankylosing Spondylitis
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received additional indication approval...
CSPC Pharmaceutical’s JMT108 Gains FDA Approval for Advanced Malignant Tumor Trials
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that it has received approval from the...
Amgen’s Uplizna Approved by FDA for IgG4-Related Disease
US biotech giant Amgen (NASDAQ: AMGN) announced that it has received marketing approval from the...
J&J’s Rybrevant SC Formulation Approved by EC for NSCLC Treatment
The European Commission (EC) has approved the subcutaneous (SC) formulation of Johnson & Johnson’s (J&J,...
J&J’s Darzalex SC Formulation Approved for Newly Diagnosed Multiple Myeloma
Johnson & Johnson (J&J, NYSE: JNJ) announced that it has received clearance from the European...
AIM Vaccine’s Serum-Free Rabies Vaccine Accepted for Review by NMPA
China-based AIM Vaccine Co., Ltd (HKG: 6660) announced that its market filing for a serum-free...
SinoMab BioScience’s SM17 Shows Promising Results in Phase Ib Atopic Dermatitis Study
Hong Kong-based biotech SinoMab BioScience Ltd (HKG: 3681) has announced positive results from the Phase...
Luye Pharma’s Toludesvenlafaxine Approved for Marketing in Macau
China-based Luye Pharma Group (HKG: 2186) announced that its extended-release depression treatment, toludesvenlafaxine (LY03005), has...
Shanxi Yanghe Medical Technology Faces Production Halt Over GMP Violation
China’s National Drug Alliance Procurement Office has imposed manufacturing suspensions on Shanxi Yanghe Pharmaceutical Technology’s...
Hansoh Pharmaceutical Secures Dual NMPA Approvals for Oncology Pipeline Expansion
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced receiving dual clinical trial approvals...
Huadong Medicine’s DR30206 Approved for Clinical Trials in Gastrointestinal Tumors
China-based Huadong Medicine Co., Ltd. (SHE: 000963) announced that it has received clinical trial approval...